Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study.

Authors

Carl Johan Rudebeck, Luc Matthieu Fornecker, Blandine Guffroy, Ludovic Fouillet, Adrien Chauchet, Adrien Caillet, François-Xavier Gros, Gabriel Brisou, Hamza Manjra, Vincent Camus, Stéphanie Guidez, Fabien Claves, David Beauvais, Maryam Idlhaj, Camille Golfier, Violaine Safar, Emmanuelle Ferrant, Emmanuel Bachy, Hervé Ghesquieres, Pierre Sesques

Published in

Haematologica. Oct 15, 2026. Epub Oct 15, 2026.

Abstract

Not available.

PMID:
42876292
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.